re: Ann: Mesoblast, Intrexon and Ziopharm to ...
In the short term I wouldn't really see this as price sensitive. It's interesting, but even if successful I certainly wouldn't expect any cashflow inflows on this for what, a decade?
SP is not going to really rocket until investors can see clear path to recurring revenue and even a dividend! We are not there yet.
The pipeline is getting enormous so this could be fueling fears that they are taking on too much work? Was it Credit Suisse that commented that management were being spread a bit thin?
In the Q&A session in the recent conference call Silviu mentioned that MSB will review their opportunities. Might be time to consider pausing on some and focus on best opportunities?
Ann: Mesoblast, Intrexon and Ziopharm to Target C, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
0.025(2.67%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 96.5¢ | 94.0¢ | $1.231M | 1.291M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 94461 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 61151 | 6 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |